Trial Profile
A Neoadjuvant Phase II Trial of Aromatase Inhibitors in Combination With Everolimus in Postmenopausal Women With Hormone Receptor Positive/HER2 Negative Breast Cancers With Low and Intermediate Risk (< 25) Oncotype Dx Recurrence Scores
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Anastrozole; Exemestane; Letrozole
- Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 12 Jan 2022 Status changed from completed to discontinued.
- 22 Jan 2021 Status changed from suspended to completed.
- 14 Dec 2019 Primary endpoint (Achievement of a PEPI score of 0 following neoadjuvant treatment with everolimus and an aromatase inhibitor) has not met, according to Results presented at the 42nd Annual San Antonio Breast Cancer Symposium